Truist raises Xencor stock price target on kidney cancer drug data
Truist Securities raised its price target for Xencor (XNCR) to $40 from $29, citing positive clinical data for XmAb819 in kidney cancer. The stock has gained 17% in a week. Truist increased peak sales estimates to $1.1B and success probability to 35%. XNCR's market cap is $2.18B, with a 91% YTD return. Other analysts also upgraded price targets based on ESMO conference data.
How this was made
The 30-second read
Why it matters
The upgrades raise expectations for accelerated approval in 2027, potentially boosting the stock.
Market read
New clinical data and analyst upgrades create a clear catalyst for Xencor, making the stock a near‑term buying opportunity.
What to watch
Potential competition from other renal‑cell therapies and the need for larger Phase II data.
Background
Truist and other analysts upgraded Xencor after the company presented Phase I XmAb819 data at the ESMO conference, citing high response rates and progression‑free survival.
Ticker impact
Truist raised Xencor's price target to $40 after new XmAb819 kidney cancer trial data presented at ESMO.
upward pressure as investors price in the encouraging efficacy and safety results.
Analyst upgrades and higher price targets reflect market belief the drug could achieve accelerated approval, supporting near‑term buying.
Market effects
Biotech sector may see renewed interest in renal‑cell carcinoma therapeutics.
US biotech stocks could benefit from the data release.
International investors tracking oncology pipelines may adjust exposure.
Counterpoint
If the data does not translate to regulatory approval, the price could be overstated.
Key entities
- companyXencor, Inc.
Biotech firm developing XmAb819 for renal cell carcinoma.
- analystTruist Securities
Raised price target to $40 based on new trial data.
